[{"id":"49f30563-60f2-4168-9062-bb633cf7a950","acronym":"","url":"https://clinicaltrials.gov/study/NCT03994796","created_at":"2021-01-18T19:38:28.337Z","updated_at":"2025-02-25T14:28:26.216Z","phase":"Phase 2","brief_title":"Genetic Testing in Guiding Treatment for Patients with Brain Metastases","source_id_and_acronym":"NCT03994796","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" KRAS • BRAF • ER • PGR • ROS1 • NTRK","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 negative","tags":["KRAS • BRAF • ER • PGR • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-01-15"},{"id":"12f81b1d-451f-4a1e-b774-333646268edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009992","created_at":"2024-06-15T04:08:56.168Z","updated_at":"2024-07-02T16:34:26.237Z","phase":"Phase 2","brief_title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","source_id_and_acronym":"NCT05009992","lead_sponsor":"University of California, San Francisco","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-06-13"},{"id":"8c91534d-fea7-416e-b7d1-5b8ca484c757","acronym":"","url":"https://clinicaltrials.gov/study/NCT03765983","created_at":"2021-01-18T18:38:07.887Z","updated_at":"2024-07-02T16:35:05.419Z","phase":"Phase 2","brief_title":"GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases","source_id_and_acronym":"NCT03765983","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • EIF4EBP1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification","tags":["HER-2 • EIF4EBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/11/2019","start_date":" 02/11/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-05-07"},{"id":"7fd8451e-e40a-4b5b-98c2-c1a67ba94776","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192981","created_at":"2021-01-18T20:26:03.024Z","updated_at":"2024-07-02T16:35:09.028Z","phase":"Phase 1","brief_title":"GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases","source_id_and_acronym":"NCT04192981","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paxalisib (GDC-0084)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-17"},{"id":"c5d4896d-d6e6-484b-a31f-c6032c673747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05183204","created_at":"2022-01-10T14:58:24.578Z","updated_at":"2024-07-02T16:35:35.748Z","phase":"Phase 2","brief_title":"Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma","source_id_and_acronym":"NCT05183204","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-26"}]